Summary of Research: Immunogenicity of Dupilumab in Adult and Pediatric Patients with Atopic Dermatitis - Summary - MDSpire

Summary of Research: Immunogenicity of Dupilumab in Adult and Pediatric Patients with Atopic Dermatitis

  • By

  • Matthew P. Kosloski

  • Ching-Ha Lai

  • Michael A. Partridge

  • Vanaja Kanamaluru

  • Ashish Bansal

  • Brad Shumel

  • Marius Ardeleanu

  • Hong Yan

  • Christine Xu

  • Ainara Rodríguez Marco

  • Jing Xiao

  • Faisal A. Khokhar

  • Guy Gherardi

  • Elisa Babilonia

  • Bolanle Akinlade

  • Albert Torri

  • John D. Davis

  • April 29, 2026

  • 0 min

Share

Objective:

To evaluate the immunogenicity of Dupilumab in both adult and pediatric patients with atopic dermatitis.

Key Findings:
  • Dupilumab demonstrated a low incidence of anti-drug antibodies in both adults and children.
  • The immunogenic response was consistent across different age groups.
  • No significant correlation was found between the presence of anti-drug antibodies and clinical efficacy.
Interpretation:

The findings suggest that Dupilumab is well-tolerated and maintains its efficacy regardless of immunogenic response.

Limitations:
  • The study may have limited generalizability due to the specific patient population.
  • Long-term effects of immunogenicity were not fully assessed.
Conclusion:

Dupilumab shows a favorable immunogenic profile in treating atopic dermatitis in both adults and children, supporting its continued use in clinical practice.

Original Source(s)

Summary of Research: Immunogenicity of Dupilumab in Adult and Pediatric Patients with Atopic Dermatitis

  • by Matthew P. Kosloski, Ching-Ha Lai, Michael A. Partridge, Vanaja Kanamaluru, Ashish Bansal, Brad Shumel, Marius Ardeleanu, Hong Yan, Christine Xu, Ainara Rodríguez Marco, Jing Xiao, Faisal A. Khokhar, Guy Gherardi, Elisa Babilonia, Bolanle Akinlade, Albert Torri, John D. Davis

  • April 29, 2026

Related Content